San Antonio, TX, December 12, 2025
Intensity Therapeutics, Inc. will present groundbreaking cancer treatment advancements at the upcoming San Antonio Breast Cancer Symposium. The event, taking place at the Henry B. Gonzalez Convention Center, serves as a key platform for the latest developments in breast cancer research. Intensity will share findings on its investigational product INT230-6, aiming to revolutionize approaches to effective and safer therapies for patients. This highlights not only the company’s commitment to advancing medicine but also enhances the economic landscape of San Antonio’s biotechnology sector.
San Antonio, TX – Intensity Therapeutics, Inc. (Nasdaq: INTS) is set to make significant strides in cancer treatment at the upcoming 2025 San Antonio Breast Cancer Symposium (SABCS). Scheduled to take place from December 9-12, 2025, at the Henry B. Gonzalez Convention Center, this annual event attracts global stakeholders in breast cancer research and treatment, highlighting the need for innovation in this critical area of medicine.
Local businesses, particularly those involved in biotechnology and healthcare, are pivotal to San Antonio’s thriving economy. With a focus on entrepreneurial innovation and the importance of streamlined regulations, it’s exhilarating to witness companies like Intensity Therapeutics leading the charge in groundbreaking research and development. Their participation at such a significant symposium underscores not only their commitment to patient care but also the broader dynamic economic growth in Bexar County.
### Intensity Therapeutics at SABCS 2025
Intensity Therapeutics is slated to present two essential posters during the SABCS. The first presentation, titled “Accelerating an Anthracycline-Free Future: A New Drug in Clinical Testing Offers Patients Hope for Safer, More Effective Breast Cancer Therapy Combinations,” will be delivered by Lewis Bender, M.S., M.A., M.B.A., who serves as the Founder, President, and CEO of Intensity Therapeutics. This session is scheduled for Thursday, December 11, 2025, from 5 p.m. to 6:30 p.m. CT.
The second presentation will focus on “Intratumoral Injections of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer: Early observations from INVINCIBLE-4-SAKK 66/22 (NCT06358573), a Phase II Randomized Clinical Trial,” presented by Dr. Andreas Müller of the Swiss Cancer Institute, set for Friday, December 12, 2025, from 12 p.m. to 1:30 p.m. CT.
### Innovative Approaches to Cancer Treatment
INT230-6, the lead investigational product from Intensity, represents a new approach to cancer treatment through direct intratumoral injection. The product combines cisplatin and vinblastine sulfate with a diffusion and cell penetration enhancer molecule. This strategic formulation enhances the delivery of potent cytotoxic drugs throughout tumors, allowing cancer cells to be effectively targeted and obliterated. The adaptability of the immune response fostered by INT230-6 showcases its potential to transform concerning cancers into manageable chronic diseases.
As a late-stage clinical biotechnology company, Intensity Therapeutics is committed to utilizing its non-covalent drug-conjugation technology, which not only seeks to eradicate tumors but also aims to bolster the immune system’s recognition of cancer cells. This means better outcomes for many patients, especially those with malignancies that have shown resistance to conventional therapies.
### The Significance of SABCS
The San Antonio Breast Cancer Symposium serves as a premier venue for disseminating innovative research and clinical advancements in breast cancer treatment. Hosted annually, the symposium features contributions from experts and academics who present cutting-edge research. Intensity’s presentations not only reflect their pioneering work but also echo the commitment of the local biotech community in striving for improved health outcomes.
### Economic Impact on San Antonio
With Intensity Therapeutics at the forefront, San Antonio reaffirms its position as a burgeoning hub for biotechnology and healthcare innovation. The success of such businesses is critical, as they contribute to local job creation, attract investments, and position the city strategically within Texas’s competitive economic landscape. Reducing regulatory burdens can further accelerate this growth, enabling local entrepreneurs to thrive and expand their operations.
### Conclusion
The upcoming presents by Intensity Therapeutics at the 2025 SABCS stand as a beacon of hope in the realm of breast cancer treatment. Their innovative approaches not only advance medical science but also contribute significantly to the local economy and community health. Supporting local businesses ensures that San Antonio remains a vital center for innovation and entrepreneurship.
As the community looks forward to the symposium, it is crucial to recognize and applaud those who are dedicated to enhancing health care and improving patient outcomes. Continued engagement in local initiatives is paramount to fostering a robust economic future for San Antonio and its residents.
Frequently Asked Questions
What is the 2025 San Antonio Breast Cancer Symposium (SABCS)?
The SABCS is a premier event for the global breast cancer community, featuring the latest research and developments in the field.
What is INT230-6?
INT230-6 is Intensity Therapeutics’ lead investigational product designed for direct intratumoral injection. It combines cisplatin and vinblastine sulfate with a diffusion and cell penetration enhancer molecule, facilitating the dispersion of potent cytotoxic drugs throughout tumors and allowing the active agents to diffuse into cancer cells.
When and where are Intensity Therapeutics’ presentations at SABCS 2025?
Intensity Therapeutics will present two posters at the 2025 SABCS:
- Title: Accelerating an Anthracycline-Free Future: A New Drug in Clinical Testing Offers Patients Hope for Safer, More Effective Breast Cancer Therapy Combinations
Date and Time: Thursday, December 11, 2025, 5 p.m. – 6:30 p.m. CT
Presenter: Lewis Bender, M.S., M.A., M.B.A., Founder, President, and CEO of Intensity Therapeutics - Title: Intratumoral Injections of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer: Early observations from INVINCIBLE-4-SAKK 66/22 (NCT06358573), a Phase II Randomized Clinical Trial
Date and Time: Friday, December 12, 2025, 12 p.m. – 1:30 p.m. CT
Presenter: Dr. Andreas Müller of the Swiss Cancer Institute
What is the focus of Intensity Therapeutics?
Intensity Therapeutics is a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology. This technology creates drug products designed to kill tumors and increase immune system recognition of cancers.
| Presentation Title | Date and Time | Presenter |
|---|---|---|
| Accelerating an Anthracycline-Free Future: A New Drug in Clinical Testing Offers Patients Hope for Safer, More Effective Breast Cancer Therapy Combinations | Thursday, December 11, 2025, 5 p.m. – 6:30 p.m. CT | Lewis Bender, M.S., M.A., M.B.A., Founder, President, and CEO of Intensity Therapeutics |
| Intratumoral Injections of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer: Early observations from INVINCIBLE-4-SAKK 66/22 (NCT06358573), a Phase II Randomized Clinical Trial | Friday, December 12, 2025, 12 p.m. – 1:30 p.m. CT | Dr. Andreas Müller of the Swiss Cancer Institute |
Deeper Dive: News & Info About This Topic
HERE Resources
San Antonio Faces Significant Population Decline
Mount Sinai Research to be Highlighted at SABCS 2025
Innovative Research on Breast Cancer at San Antonio Symposium
2025 San Antonio Breast Cancer Symposium to Showcase Groundbreaking Research
Intensity Therapeutics Presenting at San Antonio Breast Cancer Symposium
Plus Therapeutics to Present Groundbreaking Research at SABCS
Plus Therapeutics to Present Breakthrough Study on Cancer Treatment
ESMO 2025 Announces Key Events and Speakers
Author: STAFF HERE SAN ANTONIO WRITER
The SAN ANTONIO STAFF WRITER represents the experienced team at HERESanAntonio.com, your go-to source for actionable local news and information in San Antonio, Bexar County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Fiesta San Antonio, San Antonio Stock Show & Rodeo, and Dia de los Muertos. Our coverage extends to key organizations like the Greater San Antonio Chamber of Commerce and United Way of San Antonio and Bexar County, plus leading businesses in retail, insurance, and energy that power the local economy such as H-E-B, USAA, and Valero Energy. As part of the broader HERE network, including HEREAustinTX.com, HERECollegeStation.com, HEREDallas.com, and HEREHouston.com, we provide comprehensive, credible insights into Texas's dynamic landscape.
